Therapeutics for Rare and Neglected Diseases
The NCATS Therapeutics for Rare and Neglected Diseases (TRND) program is designed to encourage and speed the development of new drugs for rare and neglected diseases. TRND stimulates drug discovery and development research collaborations among NIH and academic scientists, nonprofit organizations, and pharmaceutical and biotechnology companies working on rare and neglected illnesses. Read the TRND fact sheet.
TRND collaborations offer an opportunity to partner with TRND researchers and gain access to rare and neglected disease drug development capabilities, expertise, and clinical/regulatory resources in a collaborative environment with the goal of moving promising therapeutics into human clinical trials. To foster collaborations, TRND uses an application and evaluation process to select collaborators. Selected investigators provide the drug project starting points and ongoing biological/disease expertise throughout the project.
The drug development process is complicated and expensive. Innovations in drug discovery and development and management of development programs can substantially reduce the risks, time delays and costs of advancing basic research breakthroughs into treatments. Thus, in addition developing new candidate drugs for rare and neglected diseases, the TRND program is designed to advance the entire field of drug development by encouraging scientific and technological innovations aimed at improving success rates in the crucial pre-clinical stage of development.
TRND bridges the gap that often exists between a basic research discovery and the testing of new drugs in humans. To close the gap, the work of TRND includes the discovery, optimization and pre-clinical testing of therapies, with the goal to generate sufficient quality data to support successful Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) and first-in-human studies as necessary. Therapeutic clinical candidates that reach this stage should be attractive to biotechnology and pharmaceutical companies to take into clinical development.
TRND expands upon the successes of the Molecular Libraries Program and the NIH Chemical Genomics Center. The Molecular Libraries Probe Production Centers Network initiative has produced high-quality assay screening facilities across the United States that develops probes for exploring biology and disease. However, there is often a gap between fundamental exploration of biological processes and the point at which biotechnology and pharmaceutical companies adopt these research discoveries to develop therapeutic programs. Adoption of drug development programs for rare and neglected disease therapeutics is that much more difficult due to the limited market for such drugs. Through collaborative projects, TRND leverages both public- and private-sector investments to develop new drugs for patients with rare and neglected diseases.
Through the TRND program, NCATS scientists collaborate with researchers from a broad and diverse range of scientific disciplines and disease areas. TRND encourages investigators from both within and outside the NIH to submit projects for work within its intramural facility. These ongoing collaborations benefit researchers, and more importantly, patients with rare and neglected diseases.
TRND Active Projects Portfolio
|Therapeutic Area/Disease||Organization Name(s)||Partner Type(s)|
|Autoimmune pulmonary alveolar proteinosis||Cincinnati Children’s Hospital||Academic|
|Core binding factor leukemia||National Human Genome Research Institute (NHGRI)||NIH intramural labs|
|Creatine transporter defect||Lumos Pharma, Inc.||Biotech|
|Cryptococcal meningitis||Viamet Pharmaceuticals, Inc.||Biotech|
|Fibrodysplasia ossificans progressiva||Massachusetts General Hospital||Academic|
|Hemoglobinopathies||Phoenicia Biosciences, Inc.||Biotech|
|Hereditary inclusion body myopathy||New Zealand Pharmaceuticals, NHGRI||Biotech, NIH intramural labs|
|Hypoparathyroidism||Eli Lilly & Co.||Pharmaceutical|
|Lassa fever||Kineta, Inc.||Biotech|
|LEOPARD syndrome||Beth Israel Deaconess Medical Center||Academic|
|Malaria||Loyola University Chicago||Academic|
|Niemann-Pick disease type C||Ara Parseghian Medical Research Foundation, Niemann-Pick Type C Support of Accelerated Research (NPC-SOAR), Einstein College of Medicine, University of Pennsylvania, Washington University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and National Human Genome Research Institute (NHGRI)||Disease foundation, academic, NIH intramural labs|
|Retinitis pigmentosa||University of California, Irvine||Academic|
Christopher P. Austin, M.D., NCATS Director and Acting Director, Division of Pre-Clinical Innovation
Asaf Alimardanov, Ph.D., Process Chemistry Lead
Mark Behnke, Chemistry Lead
Nuria Carrillo, M.D., Clinician
Catherine Chen, Ph.D., Biologist
Bradley Class, Postbaccalaureate Fellow
Jim Cradock, Ph.D., Formulation
Brad Gillespie, Ph.D., Director, Drug Development
Lisa Goodman, Program Assistant
Gurmit Grewal, Ph.D., Senior Scientific Officer
Wenwei Huang, Ph.D., Chemistry Lead
Pramod Joshi, Toxicologist
Jennifer Kouznetsova, M.S., Research Associate and Laboratory Manager
Arthur Lee, Chemist
Kimloan Nguyen, ADME Scientist
Elizabeth Ottinger, Ph.D., Project Manager
Andre Pilon, Ph.D., Program Analyst
Phil Sanderson, Ph.D., Project Manager
G. Sitta Sittampalam, Ph.D., Senior Scientist and Project Manager
Wei Sun, Ph.D., Biologist
Manju Swaroop, M.S., Biologist
Pramod Terse, Ph.D., Toxicology and Pharmacology Lead
Natasha Thorne, Ph.D., Biologist
Mengqiao Wang, Ph.D., Postdoctoral Fellow, Biology
Xin Xu, Ph.D., Director, ADME and PK
Nora Yang, Ph.D., M.B.A., Director, Portfolio Management and Program Operations
Wei Zheng, Ph.D., Biology Lead
New TRND Projects
On Oct. 15, 2014, NCATS announced three new pre-clinical drug development projects aimed at finding treatments for malaria, Lassa fever, and two rare blood disorders: beta-thalassemia and sickle cell disease. Read the announcement.
Industry Acquires First Drug Candidate from TRND Program
On July 9, 2014, NIH announced that biopharmaceutical company Baxter International has acquired a drug candidate developed by NCATS' Therapeutics for Rare and Neglected Diseases (TRND) researchers and collaborators. The small molecule, Aes-103, is designed to treat sickle cell disease, a genetic blood disorder that affects millions worldwide, including approximately 100,000 people in the United States — among them, 1 in 500 African-Americans.